INTRODUCTION: Vitamin D deficiency is prevalent in kidney transplant recipients (KTR) and recommendations on how to replenish vitamin D deposits are scarce. AIM: To evaluate, in KTR, the safety and efficacy of calcifediol in two different vitamin D supplementation regimens, in order to assess the most suitable dose. PATIENTS AND METHODS: Prospective observational study with two calcifediol supplementation regimens randomly prescribed by clinicians in liquid form, at 266 mcg doses, monthly or biweekly. We analyzed 168 KTR with a functioning allograft for more than 6 months. Patients receiving other vitamin D forms, calcimimetics or bisphosphonates were excluded. Before calcifediol initiation (pre-treatment levels) and after at least 3 months of treatment (post-treatment levels), we measured serum levels of 25-OH vitamin D (25(OH)D), parathyroid hormone (PTH), alkaline phosphatase (ALP), calcium (sCa), phosphate (sPO4) and creatinine (sCreat). RESULTS: In the monthly group (n = 72), 25(OH)D levels increased from 14 ng/ml [interquartile range, IQR 9-22] at baseline to 31 [20-38] (p = 0.000), PTH decreased from 124 pg/ml [87-172] to 114 [78-163] (p = 0.006), while sCa and sPO4 remained stable. In the biweekly group (n = 96), 25(OH)D increased from 14 ng/ml [9-20] at baseline to 39 [28-52] (p = 0), PTH decreased from 141 pg/ml [95-221] to 112 [90-180] (p = 0.000), sCa remained stable and sPO4 increased from 3.3 ± 0.6 mg/dl to 3.5 ± 0.6 (p = 0.003). Renal function remained stable in both groups. CONCLUSION: Vitamin D reposition with oral calcifediol, in a biweekly or monthly regimen, is safe and effective in improving 25(OH)D blood levels and in decreasing PTH in kidney transplant recipients.
INTRODUCTION:Vitamin D deficiency is prevalent in kidney transplant recipients (KTR) and recommendations on how to replenish vitamin D deposits are scarce. AIM: To evaluate, in KTR, the safety and efficacy of calcifediol in two different vitamin D supplementation regimens, in order to assess the most suitable dose. PATIENTS AND METHODS: Prospective observational study with two calcifediol supplementation regimens randomly prescribed by clinicians in liquid form, at 266 mcg doses, monthly or biweekly. We analyzed 168 KTR with a functioning allograft for more than 6 months. Patients receiving other vitamin D forms, calcimimetics or bisphosphonates were excluded. Before calcifediol initiation (pre-treatment levels) and after at least 3 months of treatment (post-treatment levels), we measured serum levels of 25-OH vitamin D (25(OH)D), parathyroid hormone (PTH), alkaline phosphatase (ALP), calcium (sCa), phosphate (sPO4) and creatinine (sCreat). RESULTS: In the monthly group (n = 72), 25(OH)D levels increased from 14 ng/ml [interquartile range, IQR 9-22] at baseline to 31 [20-38] (p = 0.000), PTH decreased from 124 pg/ml [87-172] to 114 [78-163] (p = 0.006), while sCa and sPO4 remained stable. In the biweekly group (n = 96), 25(OH)D increased from 14 ng/ml [9-20] at baseline to 39 [28-52] (p = 0), PTH decreased from 141 pg/ml [95-221] to 112 [90-180] (p = 0.000), sCa remained stable and sPO4 increased from 3.3 ± 0.6 mg/dl to 3.5 ± 0.6 (p = 0.003). Renal function remained stable in both groups. CONCLUSION:Vitamin D reposition with oral calcifediol, in a biweekly or monthly regimen, is safe and effective in improving 25(OH)D blood levels and in decreasing PTH in kidney transplant recipients.
Entities:
Keywords:
Calcifediol; Kidney transplant; Parathyroid hormone; Vitamin D
Authors: D Sawinski; J Uribarri; D Peace; T Yao; P Wauhop; P Trzcinka; K Ostrow; E D Poggio; P S Heeger Journal: Am J Transplant Date: 2010-09-14 Impact factor: 8.086
Authors: M Albalate; C de la Piedra; A Ortiz; J Hernández Pérez; M Rubert; R Pérez Garcia; P Zazo; L Nieto; P de Sequera; J Egido Journal: Nephron Clin Pract Date: 2012-11-27
Authors: Marie Courbebaisse; Eric Thervet; Jean Claude Souberbielle; Julien Zuber; Dominique Eladari; Frank Martinez; Marie-France Mamzer-Bruneel; Pablo Urena; Christophe Legendre; Gerard Friedlander; Dominique Prié Journal: Kidney Int Date: 2008-10-15 Impact factor: 10.612
Authors: C Alfieri; A Regalia; G Moroni; D Cresseri; F Zanoni; M Ikehata; P Simonini; M P Rastaldi; G Tripepi; C Zoccali; C Chatziantoniou; Piergiorgio Messa Journal: J Nephrol Date: 2019-01-10 Impact factor: 3.902
Authors: Giuseppe Cianciolo; Maria Cappuccilli; Francesco Tondolo; Lorenzo Gasperoni; Fulvia Zappulo; Simona Barbuto; Francesca Iacovella; Diletta Conte; Irene Capelli; Gaetano La Manna Journal: Nutrients Date: 2021-04-25 Impact factor: 5.717